CD37 is a tetraspanin membrane protein that functions as a structural component of tetraspanin-enriched microdomains (TERMs), serving as platforms for receptor clustering and cellular signaling 1. The protein participates in diverse biological functions including cell signal transduction, adhesion, migration, and protein trafficking 1. CD37 plays essential roles in integrin clustering, particularly promoting ITGA4/ITGB1 integrin mobility in B-cell plasma membranes and mediating antiapoptotic signaling through AKT 1. In metabolic regulation, CD37 acts as a membrane-localized inhibitor of fatty acid metabolism by directly interacting with and inhibiting the fatty acid transporter FATP1, thereby controlling lipid uptake and processing in aggressive B-cell lymphomas 2. The protein also regulates platelet hyperreactivity and thrombosis by modulating integrin αIIbβ3 signaling, with CD37 deficiency leading to impaired platelet activation and reduced thrombotic risk 3. Clinically, CD37 serves as a prognostic marker and therapeutic target in B-cell malignancies, with anti-CD37 immunotherapies showing promise in treating acute myeloid leukemia and B-cell lymphomas 45. Additionally, CD37 expression is regulated by CD20, forming a stabilizing complex that affects immunotherapy efficacy 6.